Home > Grants > Grants - Winner > 2014 Grants - Winner > Patient Capital Corporate Venture Capital and Productivity in Pharmaceutical and Biotechnology Companies

Patient Capital Corporate Venture Capital and Productivity in Pharmaceutical and Biotechnology Companies

耐心资本 In the aftermath of the 2008 financial crisis, regulators around the world have sought to reduce the amount of capital that global banks can commit to illiquid or risky asset classes. This resulted in a reduction in potential investors for traditional venture capital (VC).

Furthermore, while other investors, such as funds-of-funds, also reduced their allocations to riskier illiquid assets such as VC, corporate venture capital (CVC) has increasingly filled the void, especially in some sub-sectors (like biotechnology) in the pharmaceutical industry. In our study, we examined the financing of pharmaceutical firms and analyzed whether the type of financing is correlated with the success rate of drug development.

We hand-assembled a large dataset from two sources: proprietary data on all drugs under development in the U.S. from 1980 until 2014, and data on VC and CVC investments that company founders have received from 1987 through 2014.

We find that VC and CVC investors invest in more novel compounds, and their compounds are likely to reach Phase II of development. However, compounds coming from large pharmaceutical companies that don’t rely on VC investments are more likely to be successful and be granted approval by the Food and Drug Administration (FDA).

Our results are robust to the inclusion of various controls, including measures of compound novelty. The results are not explained by the timing of VC investments (most of these occur before the compounds reach Phase I). Further, the higher success rate of large pharma companies is not replicated in their acquisitions – compounds acquired (not developed) by pharma companies are not more likely to succeed than VC-backed compounds.


Lora Dimitrova
received her PhD from London Business School and is currently a Lecturer in Finance at the University of Exeter. Her research focuses on innovation, private equity, venture capital and entrepreneurial finance.

Juanita Gonzalez-Uribe received her PhD from Columbia University and is currently Assistant professor at the London School of Economics. Her research interests lie in the fields of entrepreneurship, private equity, and innovation.

This guest post summarizes their research on “Corporate Venture Capital and Productivity in Pharmaceutical-Biotechnology Companies”, partially funded by a $15,000 CIV Research Grant.

Paper submission for CIV 2017 Research Awards is open until 31-Jan-2017. Submit your paper now!

Check Also

Aging Ventures and Silver-Tech — A Global Megatrend Guest Post by Dov Sugarman, an Expert in Senior Care Technology

In 2015, there were approximately 1.6 billion people in the world aged 50-plus, yet by 2050, this number is projected to double. The aging of society poses both challenges and opportunities to governments and private sector companies alike and is having a transformative impact, economically and socially. The past couple of years has seen the creation of several dedicated funds targeting investments in companies developing innovative solutions for seniors, and even Silicon Valley's most famous venture capitalists have begun betting on the “silver tech” niche. Read a guest post by Dov Sugarman, an expert in senior care technology.